In response to the Office Action of November 26, 2002, please amend the application as follows:

In the Claims

Please amend claims 21-23, 25-27, 30 and 31, as follows:

--21. (Amended) Monocyclic compounds of formula (I)

wherein:



X_1, X_2, X_3, X_4 are the same or different, and are selected from the group consisting of -CONR-, -NRCO-, $-CH_2$-NR-, and -NR-CH_2- where R is selected from the group consisting of H, C_{1-3} alkyl, and benzyl;

f and m are the same or different, and is a number selected from the group consisting of 0, 1 and 2;

R_1 and R_2, are the same or different, and represent:

$-(CH_2)_r Ar$ where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy,

C_{2-4} amino-alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_3 is-$(CH_2)_rAr_1$ where r is 0, 1 or 2 and Ar_1 is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

optionally substituted with up to 2 groups selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, amino-alkyloxy, halogens, OH, NH_2, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_4 is-NR_8R_9, where R_8 is H or C_{1-3} alkyl; and

R_9 is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C_{1-3} alkyl, C_{1-3} acyl, aminosulfonyl, or methanesulfonyl; or a group-$(CH_2)gR_{10}$ where g is 1,2, or 3 and R_{10} is selected from the group consisting of morpholine, furan and CN;

or R_8 and R_9 together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom substituted by a C_{1-3} alkyl, C_{1-3} acyl or methanesulfonyl;

-$N(R_{11})CO(CH_2)_hR_{12}$ where R_{11} is H or C_{1-3} alkyl; h is 0, 1, 2 or 3; and R_{12} is selected from the group consisting of morpholine, pyrrolidine optionally substituted with a hydroxy or hydroxymethyl, piperidine optionally substituted with a 4-hydroxy, 4-carboxyamido or 4-aminosulfonyl group, piperazine optionally substituted on the N-atom by C_{1-3} alkyl, triazole, tetrazole, 5-mercapto-tetrazole, furan, thiophene, thiomorpholine, optionally mono or di-oxygenated on the S-atom, and amino- cyclohexane optionally substituted by a hydroxy group;

- COR_{13} wherein R_{13} is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C_{2-6} alkyl containing one or more hydroxy groups;

their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

22. (Amended) Compound according to Claim 21 wherein:

f is 1

C1

m is 0

X_1, X_2, X_3, X_4, are the same or different and are a member selected from the group consisting of -CONR- and -NRCO-,

where R is H or methyl,

R_1 and R_2 are the same or different, are:

$-CH_2Ar$ wherein Ar is an aromatic group selected from the group consisting of benzene, pyridine, indole, optionally substituted with up to two substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7, same or different, and are H or C_{1-3} alkyl;

R_3 is $-CH_2Ar_1$ wherein Ar_1 is an aromatic group selected from the group consisting of alpha naphthyl, beta naphthyl, phenyl, phenyl substituted with up to two substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3}alkyloxy, halogens, OH, and NH_2.

23. (Amended) Compounds according to Claim 22 wherein:

- X_1, X_2, X_3, X_4 are -CONH-,

- R_1 is indol-3-yl-methyl

- R_2 is phenyl-methyl optionally substituted with up to two substituents selected from the group consisting of chlorine, fluorine, CF_3, OH and CN, or are selected from the group consisting of 3-pyridyl-methyl and 4-pyridyl-methyl;

- R_3 is benzyl.

---

25. (Amended) Compounds according to Claim 24 represented by:

i) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

ii) cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

iii) cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

iv) cyclo{Suc[1-(R)-(4-tetrahydrothiopyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

v) cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

vi) cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

vii) cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

viii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

ix) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

x) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xi) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF3)-[(R)-NH-CH (CH_2-C_6H_5)-CH_2NH]}

C2

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xv) cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xvi) cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xvii) cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xviii) cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]} or

xix) cyclo{Suc[1-(R)-4-methylsulfonyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

26. (Amended) Compounds according to Claim 23 wherein :

R_4 represents a group NR_8R_9, where R_8 is H and R_9 is methanesulfonyl, tosyl or a group $-(CH_2)_gR_{10}$, wherein g is 1 or 2 and R_{10} is morpholine, furan, or CN.

27. (Amended) Compounds according to claim 26 represented by:

C2

xx) cyclo{Suc[1-(S)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxi) cyclo{Suc[1-(R)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxii) cyclo{Suc[1-(S)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxiii) cyclo{Suc[1-(R)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxiv)cyclo{Suc[1-(S)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxv) cyclo{Suc[1-(R)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxvi) cyclo{Suc[1-(R)-(2-furyl)methylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]} or

xxvii) cyclo{Suc[1-(R)-cianomethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

30. (Amended) Compounds according to Claim 23 wherein:

R_4 represents a group COR_{13} wherein R_{13} is morpholine.

C3

31. (Amended) Compounds according to claim 30 represented by:

xlvi) cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.